Global Antiviral Oral Liquid Market Growth (Status and Outlook) 2024-2030

Global Antiviral Oral Liquid Market Growth (Status and Outlook) 2024-2030

Antiviral Oral liquids are homogeneous liquid preparations, usually contains a solution, an emulsion or a suspension of one or more active ingredients in a suitable liquid base.

The global Antiviral Oral Liquid market size is projected to grow from US$ 3444.4 million in 2023 to US$ 4298.7 million in 2030; it is expected to grow at a CAGR of 3.2% from 2024 to 2030.

LPI (LP Information)' newest research report, the “Antiviral Oral Liquid Industry Forecast” looks at past sales and reviews total world Antiviral Oral Liquid sales in 2023, providing a comprehensive analysis by region and market sector of projected Antiviral Oral Liquid sales for 2024 through 2030. With Antiviral Oral Liquid sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antiviral Oral Liquid industry.

This Insight Report provides a comprehensive analysis of the global Antiviral Oral Liquid landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Antiviral Oral Liquid portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Antiviral Oral Liquid market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antiviral Oral Liquid and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antiviral Oral Liquid.

The future market trends of antiviral oral liquid are influenced by several factors, such as the emergence of new viral strains, the development of novel drugs, the availability of vaccines, and the consumer demand. Some of the key trends are:

Increased demand for COVID-19 treatment: The ongoing pandemic has boosted the demand for antiviral oral liquid for COVID-19 treatment. Several drugs, such as remdesivir, favipiravir, molnupiravir, and Paxzen have been approved or launched for COVID-19 treatment in different countries. The U.S. government has also invested more than USD 3 billion to accelerate the discovery and development of antiviral oral liquid for COVID-19.

Shift to generic drugs: The patent expiration of some branded antiviral drugs, such as Tamiflu and Valtrex, has opened the market for generic versions of antiviral oral liquid. Generic drugs are cheaper and more accessible than branded drugs, which can increase the market penetration and competition.

Innovation and diversification: The antiviral oral liquid market is expected to witness innovation and diversification in terms of drug class, formulation, indication, and combination therapy. For instance, Roche’s Xofluza is a novel drug that inhibits the endonuclease activity of the influenza virus. Zenara Pharma’s Paxzen is a combination of favipiravir and zinc acetate that enhances the antiviral effect6. Antiviral oral liquid can also be used for other indications, such as respiratory syncytial virus (RSV), cytomegalovirus (CMV), and dengue fever.

This report presents a comprehensive overview, market shares, and growth opportunities of Antiviral Oral Liquid market by product type, application, key players and key regions and countries.

Segmentation by type
Syrup
Oral suspension
Oral solution
Oral drop
Oral emulsion
Mixture

Segmentation by application
Adults
Children

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Roche
Novartis
Merck
GlaxoSmithKline
Johnson & Johnson
AbbVie
Sanofi
Bristol-Myers Squibb
AstraZeneca
Eli Lilly
Novo Nordisk
Amgen
Gilead Sciences
CSL
Takeda Pharmaceuticals
Bayer
Celgene
Merck KGaA
Allergan

Please note: The report will take approximately 2 business days to prepare and deliver.